ResearchPublications

Leveraging corona virus disease 2019 vaccination to promote hepatitis C screening
Abstract

Health care initiatives, such as hepatitis C virus (HCV) screening, have been greatly overshadowed by the corona virus disease 2019 (COVID-19) pandemic. However, COVID-19 vaccination programs also provide an opportunity to engage with a high volume of people in a health care setting. We collaborated with a large COVID vaccination center to offer HCV point-of-care testing followed by dried blood spot collection for HCV RNA. Additionally, this opportunity was used to evaluate the practical significance of a 5-minute version of the OraQuick HCV antibody test in lieu of the standard 20-minute test. We tested 2317 individuals; 31 were HCV antibody positive and six were RNA positive of which four were treated and reached sustained virological response. Over a third of those surveyed said they would not have participated had the test required 20 minutes.

CONCLUSION: Colocalizing HCV testing and linkage to care at a COVID vaccination clinic was found to be highly feasible; furthermore, a shortened antibody test greatly improves the acceptance of testing.

Download PDF

Full citation:
Vanderhoff A, Smookler D, Biondi MJ, Enman S, Fuliang T, Mahmood S, Crespi A, Marquez M, Van Uum R, You L, Wolfson-Stofko B, Logan R, LeDrew E, Shah H, Janssen H, Capraru C, Venier E, Feld JJ (2023).
Leveraging corona virus disease 2019 vaccination to promote hepatitis C screening
Hepatology Communications, 7 (1), e2101. doi: 10.1002/hep4.2101. PMCID: PMC9827963.